Roche’s diagnostic business has moved out of the shadows of its main medicines unit during the coronavirus epidemic, as the Swiss drugmaker confirmed its 2020 sales and profit outlook amid rising demand for its new COVID-19 tests. Basel-based Roche still expects full-year sales to grow in the low- to mid-single-digit percentage range, with core earnings per share growing broadly in line with sales at constant exchange rates, the company said on Wednesday. Group sales in the first-quarter rose 7% to 15.1 billion Swiss francs ($15.57 billion), with drugs business revenue up 7% and diagnostics rising 5% at constant …read more
Source:: Yahoo Finance
